Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant

Kim, Soojin; Park, Hyunjin; Song, Yiseul; Hong, Dezhi; Kim, Onyou; Jo, Eunhye; Khang, Gilson; Lee, Dongwon

doi:10.1016/j.biomaterials.2010.11.033

Cited by 79 publications

(65 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, clinical application of peroxalate nanoparticles is hindered by their instability in vivo (66,67). More recent peroxalate nanoparticle formulations that were generated with p-hydroxybenzyl alcohol (HBA) incorporated into the hydrophobic polymer are more stable in vivo and retain high specificity for scavenging H 2 O 2 (59). Polyoxalate is a commonly used scaffold for the polymeric HBA because of its ease of synthesis, biocompatibility, and complete biodegradation.…”

Section: Nanoformulated Antioxidant Enzymesmentioning

confidence: 99%

“…Polyoxalate is a commonly used scaffold for the polymeric HBA because of its ease of synthesis, biocompatibility, and complete biodegradation. These HBA-modified peroxalate nanoparticles have strong antioxidant and anti-inflammatory functions (59), and thus, they may have therapeutic potential in various cardiovascular diseases associated with oxidative stress and inflammation.…”

Section: Nanoformulated Antioxidant Enzymesmentioning

confidence: 99%

See 1 more Smart Citation

Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

Rosenbaugh

Savalia

Manickam

et al. 2013

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

Cardiovascular diseases, including hypertension and heart failure, are associated with activation of the renin-angiotensin system (RAS) and increased circulating and tissue levels of ANG II, a primary effector peptide of the RAS. Through its actions on various cell types and organ systems, ANG II contributes to the pathogenesis of cardiovascular diseases by inducing cardiac and vascular hypertrophy, vasoconstriction, sodium and water reabsorption in kidneys, sympathoexcitation, and activation of the immune system. Cardiovascular research over the past 15-20 years has clearly implicated an important role for elevated levels of reactive oxygen species (ROS) in mediating these pathophysiological actions of ANG II. As such, the use of antioxidants, to reduce the elevated levels of ROS, as potential therapies for various ANG II-associated cardiovascular diseases has been intensely investigated. Although some antioxidant-based therapies have shown therapeutic impact in animal models of cardiovascular disease and in human patients, others have failed. In this review, we discuss the benefits and limitations of recent strategies, including gene therapy, dietary sources, low-molecular-weight free radical scavengers, polyethylene glycol conjugation, and nanomedicine-based technologies, which are designed to deliver antioxidants for the improved treatment of cardiovascular diseases. Although much work has been completed, additional research focusing on developing specific antioxidant molecules or proteins and identifying the ideal in vivo delivery system for such antioxidants is necessary before the use of antioxidant-based therapies for cardiovascular diseases become a clinical reality.

show abstract

Section: Nanoformulated Antioxidant Enzymesmentioning

confidence: 99%

Section: Nanoformulated Antioxidant Enzymesmentioning

confidence: 99%

Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

Rosenbaugh

Savalia

Manickam

et al. 2013

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

show abstract

“…[53,54] In addition, a high concentration of GSH (about 2e10 mM) was found to present in several intracellular compartments such as cytosol, mitochondria, and cell nucleus [55]. And ROS were found to involve in inflammatory responses suggested they have great potential as a diagnostic and therapeutic biomarker for various inflammatory responses [56]. Therefore, it is of great practical significance regarding the development of drug delivery systems to engineer pH-/reduction-responsive carriers.…”

Section: In Vitro Cytotoxicity and Dox Release Of Hydrogels/nanogelsmentioning

confidence: 99%

Reduction- and pH-Sensitive lipoic acid-modified Poly(l-lysine) and polypeptide/silica hybrid hydrogels/nanogels

Zhang

Chen

Shen

et al. 2016

Polymer

View full text Add to dashboard Cite

“…It was reported that the POX-NPs demonstrated great potential as a biodegradable and biocompatible drug delivery vehicle. [19][20][21][22][23] Despite POX-NPs exhibiting promise as a class of drug delivery vehicles, there is no report of the use of nanofibers and their release profiles. The ease of synthesis and unique properties of POX have led us to develop nanofiber composites of POX for use in drug delivery applications.…”

Section: Introductionmentioning

confidence: 96%

“…This is likely due to the increase of POX matrix degradation caused by the interaction of POX and H 2 O 2 in PBS buffer. This result as can be clearly seen in Figure 4 [19][20][21][22][23] To understand the release mechanism and kinetics of PVA/POX NFs, the results of the in vitro RB-loaded nanofibers release study were analyzed using zero order, first order, Higuchi's model, and Hixon-Crowell's model. Table 3 gives the coefficient of correlation (r 2 ) values calculated for linear curves from different kinetic models obtained by regression analysis of RB release.…”

mentioning

confidence: 94%

Biodegradable poly(vinyl alcohol)/polyoxalate electrospun nanofibers for hydrogen peroxide-triggered drug release

Phromviyo

Lert-itthiporn

Swatsitang

et al. 2015

Journal of Biomaterials Science, Polymer Edition

View full text Add to dashboard Cite

Release of drugs in a controlled and sustainable manner is of great interest for treating some inflammatory diseases, drug delivery, and cosmetics. In this work, we demonstrated the control release of a drug from composite nanofibers mediated by hydrogen peroxide. Composite nanofibers of polyvinyl alcohol (PVA)/polyoxalate (PVA/POX NFs) blended at various weight ratios were successfully prepared by electrospinning. Rhodamine B (RB) was used as a model of drug and was initially loaded into the POX portion. The morphology of NFs was characterized using scanning electron microscopy (SEM). The functional groups presented in the NFs were characterized using IR spectroscopy. In vitro release behavior and cell toxicity of nanofibers were also investigated using the MTT assay. The results indicated that POX content had a significant effect on the size and release profiles of nanofibers. Microstructure analysis revealed that sizes of PVA/POX NFs increased with increasing POX content, ranging from 214 to 422 nm. Release profiles of RB at 37 °C were non-linear and showed different release mechanisms. The mechanism of drug release depended on the chemical composition of the NFs. RB release from the NFs with highest POX content was caused by the degradation of the nanofiber matrix, whereas the RB release in lower POX content NFs was caused by diffusion. The NFs with POX showed a loss of structural integrity in the presence of hydrogen peroxide as seen using SEM. The MTT assay showed that composite nanofibers had minimal cytotoxicity. We anticipate that nanofibrous PVA/POX can potentially be used to target numerous inflammatory diseases that overproduce hydrogen peroxide and may become a potential candidate for use as a local drug delivery vehicle.

show abstract

Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant

Cited by 79 publications

References 34 publications

Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

Reduction- and pH-Sensitive lipoic acid-modified Poly(l-lysine) and polypeptide/silica hybrid hydrogels/nanogels

Biodegradable poly(vinyl alcohol)/polyoxalate electrospun nanofibers for hydrogen peroxide-triggered drug release

Contact Info

Product

Resources

About